Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy

doi:10.1002/adfm.201700403

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy
	Zhao, Pengfei 2,3; Yin, Weimin 2,3; Wu, Aihua 3,4; Tang, Yisi 3,4; Wang, Jinyu 3; Pan, Zhenzhen 1,3; Lin, Tingting 3,5; Zhang, Meng 3; Chen, Binfan 3; Duan, Yifei 2
刊名	ADVANCED FUNCTIONAL MATERIALS
	2017-11-24
卷号	27 期号:44
关键词	albumin nanoparticles combination therapy mannose receptors multidrug resistance SPARC
ISSN号	1616-301X
DOI	10.1002/adfm.201700403
文献子类	Article
英文摘要	Multidrug resistance (MDR) is an issue that is not only related to cancer cells but also associated with the tumor microenvironments. MDR involves the complicated cancer cellular events and the crosstalk between cancer cells and their surroundings. Ideally, an effective system against MDR cancer should take dual action on both cancer cells and tumor microenvironments. The authors find that both the drug-resistant colon cancer cells and the protumor M2 macrophages highly express two nutrient transporters, i.e., secreted protein acidic and rich in cysteine (SPARC) and mannose receptors (MR). By targeting SPARC and MR, a system can act on both cancer cells and M2 macrophages. Herein the authors develop a mannosylated albumin nanoparticles with coencapsulation of different drugs, i.e., disulfiram/copper complex (DSF/Cu) and regorafenib (Rego). The results show that combination therapy of DSF/Cu and Rego efficiently inhibits the growth of drug-resistant colon tumor, and the combination has not been reported yet for use in anticancer treatment. The system significantly improves the treatment outcomes in the animal model bearing drug-resistant tumors. The therapeutic mechanisms involve enhanced apoptosis, upregulation of intracellular ROS, anti-angiogenesis, and tumor-associated macrophage "re-education." This strategy is characterized by dual targeting to and the simultaneous action on cancer cells and M2 macrophages, with biomimetic codelivery of a novel drug combination.
资助项目	National Basic Research Program of China (973 Program)[2014CB931900] ; National Basic Research Program of China (973 Program)[2013CB932503] ; NSFC, China[81373357] ; NSFC, China[81422048] ; NSFC, China[81673382] ; NSFC, China[81521005]
WOS关键词	TUMOR-ASSOCIATED MACROPHAGES ; COLORECTAL-CANCER ; SPARC EXPRESSION ; PANCREATIC-CANCER ; BOUND PACLITAXEL ; NAB-PACLITAXEL ; BREAST-CANCER ; LUNG-CANCER ; AUTOPHAGY ; DISULFIRAM
WOS研究方向	Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种	英语
出版者	WILEY-V C H VERLAG GMBH
WOS记录号	WOS:000416035400019
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/272396]
专题	药物制剂研究中心
通讯作者	Huang, Yongzhuo
作者单位	1.Guangxi Univ Chinese Med, Fac Pharm, 13 Wuhe Rd, Nanning 530200, Peoples R China; 2.Nanchang Univ, Coll Pharm, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, 501 Haike Rd, Shanghai 201203, Peoples R China; 4.Guangzhou Univ Chinese Med, Trop Med Inst, 12 Jichang Rd, Guangzhou 501450, Guangdong, Peoples R China; 5.Binzhou Med Univ Hosp, Dept Pharm, 661 Huanghe Rd, Binzhou 256603, Peoples R China
推荐引用方式 GB/T 7714	Zhao, Pengfei,Yin, Weimin,Wu, Aihua,et al. Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy[J]. ADVANCED FUNCTIONAL MATERIALS,2017,27(44).
APA	Zhao, Pengfei.,Yin, Weimin.,Wu, Aihua.,Tang, Yisi.,Wang, Jinyu.,...&Huang, Yongzhuo.(2017).Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy.ADVANCED FUNCTIONAL MATERIALS,27(44).
MLA	Zhao, Pengfei,et al."Dual-Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug-Resistant Cancer Therapy".ADVANCED FUNCTIONAL MATERIALS 27.44(2017).